Vasoconstriction Trial With LEO 90100 Aerosol Foam

• Status: Completed
• Trial end date: 2017-02-01

Summary

Vasoconstriction study with LEO 90100

• Phase: Phase 1

Details

• Lead Sponsor: LEO Pharma
• Treatments: Betamethasone; Betamethasone benzoate; Betamethasone sodium phosphate; Betamethasone Valerate; Betamethasone-17,21-dipropionate; Clobetasol; Cortisol succinate; Hydrocortisone; Hydrocortisone 17-butyrate 21-propionate; Hydrocortisone acetate; Hydrocortisone-17-butyrate; Mometasone Furoate